Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy
Annals of Internal Medicine · 2026
DOI: 10.7326/annals-25-02096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Internal Medicine, 2026. Verfasst von Peter Ueda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmacoepidemiology, Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden (P.U., J.…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Optic Neuropathy, Ischemic, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: There are concerns about a possible link between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and nonarteritic anterior ischemic optic neuropathy (NAION). OBJECTIVE: To examine whether use of GLP-1RAs increases risk for AION, which predominantly comprises NAION. DESIGN: Nationwide, register-based, cohort study. SETTING: Sweden, 2013 to 2024. PATIENTS: Initiators of GLP-1RAs compared with initiators of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. MEASUREMENTS: Anterior ischemic optic neuropathy in the national patient register. Adjusted risk differences (RDs) and risk ratios (RRs) were estimated using propensity score weighting. RESULTS: Median follow-up was 1.6 years (IQR, 0.7 to 3.1 years) for GLP-1RA users and 1.5 years (IQR, 0.7 to 2.9 years) for SGLT-2 inhibitor users. Sixty-two of 107 518 GLP-1RA users and 64 of 185 898 SGLT-2 inhibitor users experienced AION. Risks were 0.04% versus 0.02% (RD, 0.02% [95% CI, 0.00% to 0.03%]; RR, 1.93 [CI, 1.00 to 3.73]) at 1 year and 0.12% versus 0.07% (RD, 0.05% [CI, 0.00% to 0.10%]; RR, 1.69 [CI, 0.95 to 3.01]) at 5 years. The differences were substantially attenuated in analyses restricted to patients receiving metformin at baseline (1 year: RD, 0.01% [CI, -0.01% to 0.02%]; RR, 1.40 [CI, 0.64 to 3.05]; 3 years: RD, 0.01% [CI, -0.02% to 0.04%]; RR, 1.24 [CI, 0.68 to 2.26]; 5 years: RD, 0.02% [CI, -0.04% to 0.08%]; RR, 1.23 [CI, 0.65 to 2.33]). LIMITATION: Few outcome events, unmeasured confounding, and limited generalizability to GLP-1RA users without diabetes. CONCLUSION: The relative risk for AION was higher with GLP-1RA use compared with SGLT-2 inhibitor use in type 2 diabetes. However, absolute risks were small, and the RDs were substantially reduced in analyses restricted to patients receiving metformin to better account for confounding by diabetes severity, suggesting observed increases in risk may reflect residual confounding. PRIMARY FUNDING SOURCE: Karolinska Institutet, Swedish Society of Medicine, Swedish Research Council, and Region Stockholm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Pharmacoepidemiology, Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden (P.U., J.S., L.P., V.W.).
- Centre for Pharmacoepidemiology, Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; and Department of Epidemiology Research, Statens Serum Institut, Copenhagen, D…
- Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden (B.E.).
- Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark; and Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of…
ORCID-Profile: Peter Ueda, Jonas Söderling, Laura Pazzagli, Viktor Wintzell, Björn Eliasson, Anders Hviid, Björn Pasternak
Zitieren
APA
Ueda, P., Svanström, H., Söderling, J., Pazzagli, L., Wintzell, V., Eliasson, B., Hviid, A., & Pasternak, B. (2026). Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy. Annals of Internal Medicine. https://doi.org/10.7326/annals-25-02096
Vancouver
Ueda P, Svanström H, Söderling J, Pazzagli L, Wintzell V, Eliasson B, et al. Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy. Annals of Internal Medicine. 2026. doi:10.7326/annals-25-02096
BibTeX
@article{Ueda2026,
author = {Ueda, Peter and Svanström, Henrik and Söderling, Jonas and Pazzagli, Laura and Wintzell, Viktor and Eliasson, Björn and Hviid, Anders and Pasternak, Björn},
title = {Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy},
journal = {Annals of Internal Medicine},
year = {2026},
doi = {10.7326/annals-25-02096}
}
EUVIMED